✦ LIBER ✦

Randomized Phase II Trial of First-Line Treatment With Sorafenib Versus Interferon Alfa-2a in Patients With Metastatic Renal Cell Carcinoma

✍ Scribed by Coplen, D.E.

Book ID: 123064884
Publisher: Elsevier Science
Year: 2009
Weight: 69 KB
Volume: 2009
Category: Article
ISSN: 0084-4071
DOI: 10.1016/S0084-4071(09)79341-8

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

860 PHASE III RANDOMIZED TRIAL OF SUNITI

860 PHASE III RANDOMIZED TRIAL OF SUNITINIB MALATE VERSUS INTERFERON-ALFA AS FIRST-LINE SYSTEMIC THERAPY FOR PATIENTS WITH METASTATIC RENAL CELL CARCINOMA

✍ O. Rixe; T.E. Hutson; P. Tomczak; M.D. Michaelson; R.M. Bukowski; S. Oudard; S. 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 328 KB

Re: Phase II Trial of Sorafenib Plus Int

Re: Phase II Trial of Sorafenib Plus Interferon Alfa-2b as First- or Second-Line Therapy in Patients with Metastatic Renal Cell Cancer

✍ Fray F. Marshall 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 108 KB

Upfront, randomized, phase 2 trial of so

Upfront, randomized, phase 2 trial of sorafenib versus sorafenib and low-dose interferon alfa in patients with advanced renal cell carcinoma : Clinical and biomarker analysis

✍ Eric Jonasch; Paul Corn; Lance C. Pagliaro; Carla L. Warneke; Marcella M. Johnso 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 149 KB

## Abstract ## BACKGROUND: The objective of this study was to independently evaluate the objective response rate of sorafenib and sorafenib plus low‐dose interferon‐alfa 2b (IFN) as frontline therapy in patients with metastatic renal cell carcinoma (mRCC). ## METHODS: Untreated patients with cle

Phase II Placebo-Controlled Randomized D

Phase II Placebo-Controlled Randomized Discontinuation Trial of Sorafenib in Patients With Metastatic Renal Cell Carcinoma

✍ Ornstein, D.K.; Finley, D.S. 📂 Article 📅 2007 🏛 Elsevier Science ⚖ 56 KB

A multinational phase II trial of bevaci

A multinational phase II trial of bevacizumab with low-dose interferon- 2a as first-line treatment of metastatic renal cell carcinoma: BEVLiN

✍ Melichar, B.; Bracarda, S.; Matveev, V.; Alekseev, B.; Ivanov, S.; Zyryanov, A.; 📂 Article 📅 2013 🏛 Oxford University Press 🌐 English ⚖ 191 KB

Axitinib versus sorafenib as first-line

Axitinib versus sorafenib as first-line therapy in patients with metastatic renal-cell carcinoma: a randomised open-label phase 3 trial

✍ Hutson, Thomas E; Lesovoy, Vladimir; Al-Shukri, Salman; Stus, Viktor P; Lipatov, 📂 Article 📅 2013 🏛 The Lancet 🌐 English ⚖ 317 KB